SLCO2A1

Solute carrier organic anion transporter family member 2A1 · Q92959 · SLCO2A1 on Sugi Atlas →

7,825 patent compounds predicted against SLCO2A1, 6,213 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL1348493	0.69	3/20
SCHEMBL1348496	0.69	3/20
SCHEMBL1348498	0.69	3/20
SCHEMBL1347666	0.68	3/20
SCHEMBL1347669	0.68	3/20
SCHEMBL1347672	0.68	3/20
SCHEMBL1747671	0.67	3/20
SCHEMBL3364894	0.67	3/20
SCHEMBL1696531	0.53	3/20
SCHEMBL1696517	0.52	3/20
Unoprostone Isopropyl (SCHEMBL2552761)	0.51	3/20
Unoprostone (SCHEMBL24127)	0.37	3/20
Prostaglandin D2 (SCHEMBL2508829)	1.00	2/20
[3H]Pgd2 (SCHEMBL2508831)	1.00	2/20
SCHEMBL3368155	0.75	2/20
SCHEMBL501141	0.74	2/20
Thromboxane B2 (SCHEMBL38223)	0.73	2/20
Prostaglandin H2 (SCHEMBL2513563)	0.72	2/20
Dinoprostone (SCHEMBL25533)	0.72	2/20
Dinoprostone (SCHEMBL239769)	0.72	2/20

Clinical trials — most relevant to SLCO2A1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Impact of Polymorphisms of OCT2 and OCTN1 on the Kinetic Disposition of Gabapentin in Patients Undergoing Chronic Use	PHASE4	COMPLETED
Organic Cation Transporter 1 (OCT1), on Response to Metformin in Healthy Subjects	PHASE4	COMPLETED
Genetic Basis for Variation in the Renal Elimination of Metformin	PHASE4	COMPLETED
The Interaction of Herbs and Statins	PHASE4	COMPLETED
Effect of Age on the Renal Clearance of Adefovir	PHASE4	WITHDRAWN
A Study Comparing CO-1.01 With Gemcitabine as First Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma (LEAP)	PHASE2	COMPLETED
Open Label Pharmacokinetic-Pharmacogenetic Study on Polymorphisms in the Organic Cation Transporter OCT1	PHASE1	COMPLETED
THE EFFECT OF CYP3A5 GENOTYPE ON THE PHARMACOKINETICS OF MARAVIROC	PHASE1	COMPLETED
Statin Therapy to Improve Medication Adherence	PHASE1	COMPLETED
Genetic Variation in Organic Cation Transport 1 (OCT1) and Its Significance for Morphine Pharmacokinetics	PHASE1	COMPLETED
Effect of, OAT3, on the Renal Secretion of Cefotaxime	PHASE1	COMPLETED
PK Study of Oral and IV Clofarabine in High Risk Myelodysplasia+Acute Leukemias	PHASE1	COMPLETED
Identification and Validation of Biomarkers for Breast Cancer Resistance Protein (BCRP)	PHASE1	COMPLETED
Drug-drug Interaction Study in Healthy Male Volunteers Following the Administration of Pantoprazole and Rosuvastatin	PHASE1	COMPLETED
Abacavir Pharmacokinetic Study in the Absence/Presence of Darunavir/Ritonavir or Raltegravir in HIV-infected Subjects	PHASE1	COMPLETED
Pharmacokinetic Drug-Drug Interaction Study to Identify Biomarkers of Kidney Transporters	EARLY_PHASE1	COMPLETED
Gadoxetate Sodium Enhanced MRI as a Biomarker for Aggressive Prostate Cancer	EARLY_PHASE1	UNKNOWN
Immune Checkpoint Inhibitor (ICI)-Drug-Drug Interaction (DDI) Study	EARLY_PHASE1	NOT_YET_RECRUITING
Metformin Gastrointestinal Intolerance: Measurement of Mitochondrial Complex I	EARLY_PHASE1	COMPLETED
Impact of Polymorphisms of OAT1, OAT3, and OCT2 on Transportation of Potential Nephrotoxic Drugs	nan	COMPLETED
Cancer and Hearing Loss Related in Children	nan	COMPLETED
SLC13A5 Deficiency Natural History Study - Remote Only	nan	ENROLLING_BY_INVITATION
The Furosemide Stress Test, Electrolytes Response and Renal Index in Critically Ill Patients	nan	COMPLETED
Renal and Hepatic Clearance Following High-Dose Methotrexate in Childhood ALL	nan	COMPLETED
PET/CT Scans Using the Tracer 11C-Csar, a Bile Acid Analog, to Depict and Visualize Cholestatic Disorders in Patients with Genetic Liver Disorders and Healthy Individuals	nan	ENROLLING_BY_INVITATION
Integrating Pharmacogenetics In Clinical Care	nan	COMPLETED
Genetics of Hyperuricemia Therapy in Hmong	nan	COMPLETED
Impact of Genetics on Metformin Pharmacokinetics	nan	COMPLETED
Placental Transfer of Tenofovir	nan	COMPLETED
Understanding Methotrexate Induced Gastrointestinal Intolerance in Juvenile Idiopathic Arthritis and Childhood Leukemia	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a SLCO2A1 binder may also engage these)

Protein	Name	Similarity
Q9EPT5	—	1.000	Q9EPT5 →
Q00910	—	0.998	Q00910 →
Q8BXB6	—	0.993	Q8BXB6 →
Q9JHI3	—	0.992	Q9JHI3 →
SLCO2B1	Solute carrier organic anion transporter family member 2B1	0.987	landscape →
Q91YY5	—	0.975	Q91YY5 →
P46720	—	0.975	P46720 →
Q924V4	—	0.975	Q924V4 →
Q9UIG8	—	0.973	Q9UIG8 →
Q8HYW2	—	0.972	Q8HYW2 →
Q8K078	—	0.972	Q8K078 →
P70502	—	0.971	P70502 →
O35913	—	0.971	O35913 →
Q8R3L5	—	0.970	Q8R3L5 →
Q9ERB5	—	0.970	Q9ERB5 →
Q99N01	—	0.970	Q99N01 →
Q8BPX9	—	0.970	Q8BPX9 →
Q4LE88	—	0.970	Q4LE88 →
Q9EP96	—	0.970	Q9EP96 →
Q99N02	—	0.969	Q99N02 →
Q9QXZ6	—	0.969	Q9QXZ6 →
O08966	—	0.969	O08966 →
O88397	—	0.968	O88397 →
Q9NYB5	—	0.968	Q9NYB5 →
Q8MJI6	—	0.968	Q8MJI6 →
Q9EPZ7	—	0.968	Q9EPZ7 →
Q9R0W2	—	0.967	Q9R0W2 →
SLC5A11	Sodium/myo-inositol cotransporter 2	0.967	landscape →
Q99J94	—	0.967	Q99J94 →
O77504	—	0.967	O77504 →